Table 2 Phase 3 trials evaluating... | American Society of Hematology

Table 2

Phase 3 trials evaluating salvage regimens in relapsed/refractory DLBCL

Study	Patients (n)	Regimens	ORR (%)	ASCT (%)	3- to 4-year* EFS	P value	3- to 4-year* OS	P value
CORAL	396	R-DHAP	63	54	35	.6	51	.4
Gisselbrecht et al¹⁰⁹	396	vs R-ICE	64	50	26	.6	47	.4
NCIC-CTG†	619	(R)-DHAP	44	49	26	.95	39	.78
Crump et al¹⁰⁸	619	vs (R)-GDP	45	52	26	.95	39	.78

Study	Patients (n)	Regimens	ORR (%)	ASCT (%)	3- to 4-year* EFS	P value	3- to 4-year* OS	P value
CORAL	396	R-DHAP	63	54	35	.6	51	.4
Gisselbrecht et al¹⁰⁹	396	vs R-ICE	64	50	26	.6	47	.4
NCIC-CTG†	619	(R)-DHAP	44	49	26	.95	39	.78
Crump et al¹⁰⁸	619	vs (R)-GDP	45	52	26	.95	39	.78

ASCT (%), percentage of patients proceeding to ASCT; ORR, overall response rate.

CORAL study reports 3-year EFS and OS; NCIC-CTG study reports 4-year EFS and OS.

NCIC-CTG trial also included transformed lymphoma and T-cell lymphoma.